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Summary
Scientific and technological advances in our under-
standing of the nature and consequences of human
genetic variation are now allowing genetic determi-
nants of susceptibility to common multifactorial
diseases to be defined, as well as our individual
response to therapy. I review how genome-wide
association studies are robustly identifying new dis-
ease susceptibility loci, providing insights into dis-
ease pathogenesis and potential targets for drug
therapy. Some of the remarkable advances being
made using current genetic approaches in Crohn’s
disease, coronary artery disease and atrial fibrillation
are described, together with examples from malaria,
HIV/AIDS, asthma, prostate cancer and venous
thrombosis which illustrate important principles
underpinning this field of research. The limitations
of current approaches are also noted, highlighting
how much of the genetic risk remains unexplained
and resolving specific functional variants difficult.
There is a need to more clearly understand the sig-
nificance of rare variants and structural genomic
variation in common disease, as well as epigenetic
mechanisms. Specific examples from pharmacoge-
nomics are described including warfarin dosage and
prediction of abacavir hypersensitivity that illustrate
how in some cases such knowledge is already
impacting on clinical practice, while in others pro-
spective evaluation of clinical utility and cost-
effectiveness is required to define opportunities for
personalized medicine. There is also a need for a
broader debate about the ethical implications of cur-
rent advances in genetics for medicine and society.
Introduction
The translation of recent advances in our under-
standing of the genetic basis of common multifactor-
ial diseases into clinical practice remains limited.
However, the extraordinary pace of change in
human genetics means that this field of research is
now starting to challenge how we understand and
manage disease, with opportunities for new insights
into pathogenesis, drug development and the
tailoring of clinical care for the individual patient.
This review provides an introduction to the nature
of human genetic variation and its functional
consequences for disease. Recent insights into the
role of genetic diversity in a number of important
common diseases serve to illustrate both the
advances achieved to date and the challenges that
lie ahead.
Approaches to defining genetic
determinants of common disease
Linkage and association
Considerable success was achieved using linkage
analysis and positional cloning (for a definition of
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Appendix 1) to identify rare variants with high pene-
trance responsible for diseases showing a mendelian
pattern of inheritance such as cystic fibrosis and
haemochromatosis.
1,2 In contrast, progress in defin-
ing genetic susceptibility loci in common multifac-
torial diseases remained frustratingly slow until
the advent of genome-wide association studies
in 2005.
3 Prior to this time, the application of a
linkage-based approach to common ‘complex’
traits was recognized to be of limited value as mul-
tiple genetic loci were likely to be involved in con-
junction with environmental factors; moreover, in
contrast to mendelian disorders, the underlying
genetic variants were of low penetrance, relatively
high allele frequency and typically associated with a
modest magnitude of effect.
3–6 Despite this, there
were some notable successes involving linkage
studies such as in Crohn’s disease with the demon-
stration of the important contribution of nucleotide-
binding oligomerization domain containing 2
(NOD2) variants as will be described shortly.
Studies seeking evidence of genetic association in
common diseases using a candidate gene approach
were in general underpowered to detect variants
associated with a modest magnitude of effect and
were not able to dissect the complex underlying
genomic architecture of coinherited variants. This
was incompletely understood until recently and typ-
ically studies analysed only a limited number of
single-nucleotide polymorphisms (SNPs) as genetic
markers, making resolution of specific variants diffi-
cult. These factors, together with the complexities of
gene–gene and gene–environment interactions,
meant that the results of candidate gene association
studies were often difficult to interpret and repli-
cate.
7 There were, however, some notable successes
achieved through a candidate gene approach with
gene selection based on biological plausibility, for
example important genetic determinants of suscep-
tibility to human immunodeficiency virus 1 (HIV-1)
and malaria were resolved, together with resistance
to new variant Creutzfeldt–Jakob prion disease and
norovirus diarrhoea.
8–11 An important component to
many of these discoveries were initial insights based
on microbial challenge experiments or observation
of extreme clinical phenotypes.
11
Genetic variation and application of
genome-wide association studies
The sequencing of the human genome provided a
route map to catalogue and interpret genetic varia-
tion among individuals.
12,13 The scale of diversity is
vast, ranging from microscopically visible variation
at the level of individual chromosomes to variation
at the deoxyribonucleic acid (DNA) sequence level
with nucleotide substitutions, insertions and dele-
tions, including >10 million SNPs (dbSNP, http://
www.ncbi.nlm.nih.gov/projects/SNP/) (Figure 1).
14
Submicroscopic structural variation, notably copy
number variation, is increasingly recognized and
plays a critical role in a number of different dis-
eases.
15–17A number of major collaborative studies,
such as the International HapMap Project, aim to
understand the genomic architecture of human
genetic variation based on very extensive genotyp-
ing of common SNPs among different ethnically
diverse human populations (http://www.hapmap
.org).
18,19 This work, together with other studies,
enabled a much clearer understanding of how
sequence variants are coinherited, with important
advances in understanding linkage disequilibrium
and haplotypic structure (Figure 2).
20,21
This has provided a remarkable resource of
sequence level diversity in the form of common
SNP markers and showed how considerable econo-
mies of scale could be achieved based on genotyp-
ing informative SNPs (sometimes described as ‘tag
SNPs’) which define particular haplotypes. This,
together with major advances in the technologies
needed for accurate, affordable and high throughput
genotyping, has enabled the successful application
of genome-wide association studies in a number of
common diseases, ranging from early successes with
age-related macular degeneration
22 to type 1 diabe-
tes
23 and Crohn’s disease.
24 There have also been
very significant advances in our ability to statistically
analyse and interpret such data, exemplified by the
Wellcome Trust Case Control Consortium (WTCCC)
study of seven common diseases.
25 This study high-
lighted the utility in a UK population of common
controls for multiple diseases as well as the ability
of genome-wide genotyping data to resolve poten-
tial population stratification. The WTCCC also
showed the value of statistical approaches to infer
(by a process described as imputation) additional
genotypes based on the genomic architecture from
the HapMap studies to allow finer resolution of
observed associations. Growing numbers of
genome-wide association studies have underlined
the importance of sample size to ensure adequately
powered studies able to detect small effect sizes;
of replication in independent samples given the
issues relating to statistical correction for multiple
testing when hundreds of thousands of SNP markers
are analysed for evidence of association; and the
persisting ‘winners curse’ in association studies in
which initial studies will tend to overestimate the
magnitude of association. Clear, minimally hetero-
geneous phenotypes and substantially increased
758 J.C. Knightsample sizes involving tens of thousands of cases
together with meta-analysis are currently advocated
to allow detection of smaller odds ratios (typically
<1.5).
Challenges to be addressed
A note of caution is, however, appropriate as despite
the successes of genome-wide association studies,
only a minority of the attributable genetic risk is
typically being explained for a given disease. This
may be improved by larger studies with increasing
numbers of common SNP markers but there may be
other explanations. For example, we are not yet able
to effectively assess the contribution of low pene-
trance, less common alleles.
26 There is also increas-
ing interest in rare variants and the role of structural
genomic variants which have until recently been
very hard to detect and analyse. Technological
advances in high throughput sequencing and micro-
array-based comparative genome hybridization are
rapidly advancing this field, the latter allowing
detection of increasingly small structural variants
such that the extent of copy number variation
across the human genome is now being appreciated
and associated with susceptibility to a number of
common diseases ranging from Parkinson’s disease
to HIV-1 infection.
27–30 Such technologies have
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Figure 1. Classes of genetic variation. Classification of genetic variation based on size according to Scherer and colleagues
with illustrations of a single-nucleotide substitution, a copy number variant and presence of an additional chromosome.
Reproduced and adapted by permission from Macmillan Publishers Ltd: Nat Genet
14 copyright (2007) and Nat Rev Genet
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(2004); and http://www.sanger.ac.uk/humgen/cnv/.
Genetics and the general physician 759significant potential clinical utility, for example in
relation to causes of learning disability,
31,32
although issues relating to predictive value for spe-
cific phenotypes and clinical outcomes need to be
resolved before such testing could be considered
evidence based. Finally, it is clear that gene–gene
and gene–environment interactions play an impor-
tant and potentially confounding role in current
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Figure 2. Linkage disequilibrium and haplotypes. (A) For a C>T SNP, the minor T allele shows association with cases of
disease, being present twice as often as in controls. (B) However, when further variants are genotyped, a second G>C SNP
shows perfect linkage disequilibrium with the initial disease associated SNP: everyone who has the T allele of the first SNP
always has the C allele of the second SNP and it is not possible to say whether the disease association is due to the first or
second SNP. (C) For four SNPs there are 16 possible combinations in which they could theoretically occur together in a
population. However, variants occur together more often than expected by chance and the observed coinherited blocks of
variants are described as haplotypes, of which three are present in this theoretical population sample. (D) Haplotype blocks
break down at sites of recombination. Understanding the haplotype block structure of the genome across populations is
highly informative for population genetics studies.
20
760 J.C. Knightapproaches, which also do not account for epige-
netic effects.
Recent genome-wide associations have been sci-
entifically compelling and have highlighted a
number of new biological pathways in disease pro-
cesses, as highlighted by studies in Crohn’s disease
described below, but it is unclear the extent to
which we are ready to use such information in a
clinical arena. The prediction of risk is complex
and at present it has been advocated that our esti-
mation of risk remains imprecise for possession of
particular genetic variants, and indeed is likely to
change in magnitude as more data are accumu-
lated.
33 Moreover, how we combine possession of
individual variants into a ‘total genetic risk’ score in
a clinically validated manner remains in its infancy,
and the use and interpretation of genetic testing
for individual patients, particularly in a ‘direct-to-
consumer’ setting, remains highly controversial.
34,35
Careful prospective clinical evaluation considering
sensitivity, specificity, predictive value of testing,
relationship with outcome and cost-effectiveness
need to be combined with wider public and patient
education to establish clear guidelines and ethical
processes for regulated implantation of genetic test-
ing in common diseases.
36,37
Coronary artery disease and atrial
fibrillation
Among the many associations found in the WTCCC
study, the association of coronary artery disease
with SNP markers on chromosome 9p21.3 high-
lights both the excitement and the work remaining
to be done inherent in current genome-wide associ-
ation studies. This was the most significant associa-
tion seen across the genome for this disease and
has been independently replicated in different popu-
lations.
25,38–40 Meta-analysis of >12000 cases and
29000 controls shows that possession of each
copy of the risk allele is associated with an odds
ratio of 1.24 (95% confidence interval 1.20–
1.29).
41 The magnitude of risk is relatively modest
but highly significant; the biological mechanism is
unknown although nearby are CDKN2A and
CDKN2B, genes encoding cyclin-dependent kinase
inhibitors involved in cancer cell biology with a
postulated role in atherosclerosis through modula-
tion of transforming growth factor beta.
Intriguingly, there is now evidence of a large non-
coding ribonucleic acid (RNA) in the risk locus,
ANRIL, specific transcripts of which are differentially
expressed in the presence of the risk allele which is
thought to relate to regulatory variants in a con-
served enhancer element.
42 This correlates with
altered expression of CDKN2B consistent with a reg-
ulatory role for ANRIL and is postulated to modulate
disease by altering cellular proliferation.
Further work is required to resolve specific regu-
latory variants and the functional mechanisms
involved. However, the disease association may
prove highly informative in terms of both novel
insights into pathogenesis and in the clinic. A pro-
spective study, for example, shows a role in risk
assessment for predicting the presence of angio-
graphic coronary artery disease but not severity,
which is independent of family history and other
known risk factors,
43 although a recent study of car-
diovascular disease in the Women’s Genome Health
Study found no benefit in risk prediction.
44 It is also
striking that within 10kb on a neighbouring linkage
disequilibrium block is a SNP marker showing
strong association with type 2 diabetes,
45–47
although the specific variants and their functional
consequences relating to coronary artery disease
and type 2 diabetes at 9p21 remain unknown.
Success has also been achieved using genome-
wide association studies in atrial fibrillation with
association at chromosome 4q25.
48 Again, exten-
sive replication has confirmed this association
among individuals of North European descent with
a meta-analysis showing an odds ratio of 1.9
(1.6–2.26) for the most strongly associated SNP
with atrial fibrillation.
49 In this case, the associated
SNP is in a gene desert 50000 bases away from
the nearest gene, but that gene is particularly intri-
guing as it is paired-like homeodomain 2 (PITX2)
which encodes a transcription factor important to
cardiac development, notably the sleeve of cardiac
tissue extending out over the pulmonary vein known
to be important in the aetiology of atrial fibrillation
and the target of therapeutic ablation therapy for this
condition.
50 Further work is needed to resolve the
specific variants responsible for this association, but
the result illustrates how an unbiased genetics
approach has implicated a specific regulatory pro-
tein which may unlock the underlying mechanism
of disease.
Insights from Crohn’s disease
Research in Crohn’s disease highlights many impor-
tant issues related to the genetics of common dis-
ease. The pathological basis of this disease is
thought to involve an environmental trigger such
as an infectious agent(s) leading to disease in genet-
ically susceptible individuals. An early striking result
was achieved through genome-wide linkage analy-
sis which identified a major genetic risk locus
51 and
subsequently specific coding SNPs within the
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52–54 NOD2 encodes a protein critical
to the recognition of bacteria and subsequent proin-
flammatory response. Individuals inheriting one risk
allele have an odds ratio of 2.4 (2–2.9) for disease
compared to those without a copy, this increases to
17.1 (10.7–27.2) for carriage of at least two risk
alleles.
55
The advent of genome-wide association studies
has dramatically increased the number of genetic
susceptibility loci in Crohn’s disease to over
30.
24,56 It was notable, however, that initial scans
did not highlight the known role of NOD2 as the
panel of SNP markers did not include the known
coding variants associated with disease risk.
Significant association was seen for a genotyped
SNP in modest linkage disequilibrium with those
variants, but the observed effect size was consider-
ably lower (odds ratios of 1.3 and 1.9 for heterozy-
gotes and homozygotes, respectively), showing how
SNP coverage on the genotyping platform used can
be very important.
25 Overall, the effect sizes seen
with the many highly significant new susceptibility
loci in Crohn’s disease are modest, usually of the
order of 1.5-fold. This is a typical finding in
genome-wide association scans of common multi-
factorial diseases and highlights how, even with sev-
eral thousand cases, such studies are relatively
underpowered.
24
Genomic signposts
It is important to remember that genome-wide asso-
ciation studies are using SNPs as markers to define
association. The finding of association does not
imply causation to that particular variant but rather
the first insights into the likely genomic location of
functionally important variants. This could be com-
pared to planting a signpost in a highly variable
landscape to indicate the region of interest and help-
ing to guide us in the right direction on the path to
resolving causative variants. The ‘fine mapping’ of
disease associations represents a major hurdle still to
be overcome, both at the level of understanding
exactly what variation is present to more clearly
resolve the genetic association, and in establishing
the functional significance of specific variants.
57
Approaches currently employed in fine mapping
loci identified by genome-wide association studies
include denser genotyping of specific regions and
local resequencing, although to uncover rare and
structural genomic variants relatively large numbers
of individuals may need to be analysed using
sophisticated approaches. Coinheritance or linkage
disequilibrium between variants adds considerably
to the difficulties of fine mapping as it can be very
hard to dissect apart the effects of individual
variants. It is worth noting that functional effects
may be operating at a considerable distance,
in Crohn’s disease, for example, strong hits of asso-
ciation have been found within ‘gene deserts’ in
which associated SNP markers are far from any
known gene.
Relationship to structural genomic
variation
A further insight into genome-wide association stu-
dies in Crohn’s disease is the recent striking result
that a large deletion, involving 20kb of DNA
upstream of the immunity-related GTPase family,
M( IRGM) gene, is responsible for the observed asso-
ciation with SNP markers at that gene.
25 The pres-
ence of this deletion, which is associated with
increased disease risk, significantly altered levels
of gene expression.
58 Similar structural variation,
notably copy number variation, is likely to underpin
many observed disease associations found using
DNA sequence variants.
Insights into disease pathogenesis
The association with IRGM suggested that autop-
hagy may play an important role in Crohn’s disease
pathogenesis, an unexpected result added further
credence by the association with ATG16 autophagy
related 16-like 1 (ATG16L1).
59,60 An additional
novel insight into disease pathogenesis is the
strong association with variants involving genes in
the interleukin 23 receptor (IL23R) signaling path-
way.
60,61 IL23 plays a key role in innate and
T-cell-mediated intestinal inflammation
62 and the
significance of the association with IL23R SNPs is
substantially increased by the finding of disease
association with variants in genes that are part of
the IL23 signalling pathway namely interleukin
12B (IL12B), signal transducer and activator of tran-
scription 3 (STAT3) and Janus kinase 2 (JAK2).
24
Lessons from infectious diseases
including HIV and malaria
Functional consequences of genetic
variants in malaria
Malaria has exerted a major selective pressure on
genetic diversity in human populations and provides
elegant examples of how variants may exert their
functional effects.
10 It bears repetition to briefly con-
sider again two classic examples from this field,
namely sickle cell and Duffy blood group antigen,
to highlight how functional consequences may
operate at a structural level (changing the structure
762 J.C. Knightand function of the encoded protein) or by variation
in noncoding DNA modulating levels of gene
expression. In the former case, the selective advan-
tage gained by individuals with sickle cell trait
(having one copy of the allele encoding haemoglo-
bin S) in areas endemic for Plasmodium falciparum
has driven a monogenic disorder to high allele fre-
quencies in particular populations notably in sub-
Saharan Africa.
63 Hemoglobin S results from an
A to T nucleotide substitution in the coding
sequence of the hemoglobin beta (HBB) gene
which leads to an amino acid substitution from glu-
tamic acid to valine and a radically altered pheno-
type in terms of malarial disease risk, in particular
protection from severe manifestations of the
disease.
64
Malaria provides a further example of the conse-
quences of diversity at the level of gene regulation
through a SNP modulating expression of the duffy
antigen receptor for chemokines gene (DARC) (also
known as the FY gene). Individuals who do not have
the Duffy blood group antigen on the surface of their
red blood cells are completely protected from P.
vivax malaria.
65 This failure of expression is the
result of a T to C nucleotide substitution in the reg-
ulatory sequence (the promoter region) found
upstream of the DARC gene which disrupts the bind-
ing of the transcription factor GATA-1, a protein
which binds DNA and helps regulate gene expres-
sion (Figure 3).
66
Consideration of these two examples serves as an
introduction to the functional consequences of
genetic diversity.
57 Early work focused on variation
in coding DNA, but more recently it is clear that
variation in noncoding DNA is also important.
67
The consequences are wide ranging for the magni-
tude and timing of gene expression at the transcrip-
tion level, as well as how RNA is alternatively
spliced, its stability and processing.
68
HIV-1 and the chemokine (C-C motif)
receptor 5 32 deletion
Like malaria, research into human immunodefi-
ciency virus (HIV)/acquired immunodeficiency syn-
drome (AIDS) has advanced our understanding of
the nature and implications of genetic variation.
9
Host genetic factors have now been found to oper-
ate at a number of different levels in relation to HIV-
1, including how the virus gains entry into cells,
barriers to infection within cells and modulation of
cell-mediated and -innate immunity.
Sequencing the CC chemokine receptor CCR5
gene (the major host coreceptor protein for HIV-1)
among individuals who were HIV-1 seronegative
and whose T cells were resistant to viral infection
revealed a 32bp deletion which leads to a frame-
shift and dramatic truncation of the protein such that
the receptor fails to be expressed on the cell sur-
face.
69 When present in a homozygous state, the
RNA
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P. vivax trophozoite
DARC gene
Red cells resistant to 
merozoite invasion GATA-1 binding site lost 
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Figure 3. Duffy blood group antigen and P. vivax malaria. Schematic representation of how an A to G SNP disrupts a GATA-
1 binding site resulting in loss of expression of the DARC gene and hence the cell surface expression of the receptor that
renders red blood cells resistant to invasion by the malarial parasite. The effect of the SNP is highly specific to red blood cells
where the transcription factor GATA-1 is found. Selective advantage is thought to have driven the variant to a very high allele
frequency in Africa such that it is almost universally found in most West and Central African populations. Reproduced from
57
by permission of Oxford University Press.
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cells.
69–71 When a single copy is inherited, the con-
sequences are dependent on other variation invol-
ving the second allele.
72–74 This highlights both the
important role of structural variation in common dis-
ease and of the CCR5 coreceptor which is now a
drug target through reversible small molecule
antagonists such as maraviroc.
75
Copy number variation and HIV-1
Research into genetic susceptibility to HIV-1 also
highlighted how copy number variation may modu-
late susceptibility to common disease with the dis-
covery that possession of lower numbers of copies of
the chemokine (C-C motif) ligand 3-like 1 (CCL3L1)
gene, when compared to the median for a given
population, were highly significant in terms of sus-
ceptibility to HIV-1 and rate of disease progres-
sion.
28 CCL3L1 is a natural ligand of CCR5 that
inhibits infection of cells by HIV-1 strains which
use this coreceptor. Increased expression seen with
higher copy number is thought to result in more
binding to CCR5 and reduced accessibility to HIV-1.
Genetic determinants of viral load
HIV-1 infection also provides an elegant example of
how genome-wide association scans can be applied
to other phenotypes, in this case to the amount of
virus in plasma during the asymptomatic phase prior
to AIDS (the viral set point). This has been found to
vary significantly between patients with variants in
the major histocompatibility complex (MHC) on
chromosome 6 explaining about 15% of the
observed variability in viral load.
76 The observed
associations are intriguing, as the most strongly asso-
ciated SNP marker is within HLA complex P5
(HCP5), a gene itself thought to have arisen from
an endogenous retroviral element. Expression of
this gene may potentially interfere with the virus
but more likely the association is due to linkage
disequilibrium with HLA-B
5701. The second stron-
gest association is with a SNP near to HLA-C, which
is also associated with expression of HLA-C.
Human leukocyte antigen, killer-cell
immunoglobulin-like receptors and HIV-1
Genetic variation in the MHC, notably human leu-
kocyte antigen (HLA) class I alleles such as HLA-B57
and HLA-B35, are important determinants of disease
progression. For example, individuals homozygous
for HLA-B
35 progress to AIDS in half the median
time of those without a copy.
77 The situation is,
however, complex as diversity in other genomic
loci, specifically the highly polymorphic KIR genes
encoding killer immunoglobulin-like receptors, is
important with the combination of high expressing
KIR allotypes and specific HLA-B alleles most infor-
mative for AIDS progression and levels of HIV-1
RNA.
78
Pharmacogenomics: abacavir
hypersensitivity
HLA-B
5701 and HIV-1 also provide one of the few
clear examples of how knowledge of genetic varia-
tion can directly impact on clinical care in terms of
drug use, in this case to avoid drug hypersensitivity.
There is now robust evidence from a prospective,
randomized, multicenter, double-blind study of
nearly 2000 adult patients infected with HIV-1 that
prospective screening for this HLA allele can elimi-
nate immunologically proven hypersensitivity reac-
tions to abacavir, a reverse transcriptase inhibitor
used to treat HIV-1.
79 This is thought to involve
the endogenous pathway for antigen presentation
and is highly specific to HLA-B
5701 and not closely
related alleles, with the drug or a metabolite of it
interacting directly with the antigen-binding cleft
or modifying it to allow self-antigens to bind.
80
There is also recent evidence from a genome-wide
association study linking possession of HLA-B
5701
with risk of drug-induced liver injury due to
flucloxacillin.
81
Gene expression, asthma and
regulatory variants
Gene expression varies between individuals and has
been successfully mapped as a quantitative trait in
model organisms and more recently in humans.
82,83
Genome-wide mapping of disease association and
of global gene expression offers a complimentary
and synergistic approach, which was elegantly
demonstrated by a recent study of asthma. Here, a
strong signal of disease association was found at
chromosome 17q21 which replicated in different
European populations; analysis of gene expression
showed that the same SNPs were also those most
strongly associated with expression of a neighboring
gene, ORM1-like 3 (ORMDL3) (Figure 4).
84 The
SNPs accounted for 30% of the variance in expres-
sion of this gene which encodes a widely expressed
transporter protein.
Efforts to map variants associated with gene
expression have highlighted the role of regulatory
variants in particular classes of genes such as encod-
ing cellular chaperones, cell cycle, RNA processing
and immune function. Improved understanding
764 J.C. Knightof gene regulation through characterization of regu-
latory elements across the genome by projects such
as ENCODE (ENCyclopedia Of DNA Elements)
(http://www.genome.gov/10005107) will provide a
route map to identify functional variants. Effects
are likely to be highly context specific, for example
to specific cell or tissue types, developmental stages
or particular cellular conditions.
67
Genome-wide association studies
and prostate cancer
Many new susceptibility loci have been defined
among common cancers occurring in European
populations (breast, lung, colorectal, prostate and
melanoma) through the application of genome-
wide association studies over the last 3 years.
85
These germline variants are associated with
modest increased risks (typically odds ratios <1.3)
although as they are typically relatively common,
the population attributable risk is higher.
Moreover, for the individual, possession of multiple
risk alleles may confer a relatively large risk.
Genome-wide association studies using common
SNP markers have highlighted the polygenic
nature of the identified genetic risk for these cancers,
but taking into account the rare high penetrance
variants (such as involving BRCA1 and BRCA2 in
breast and ovarian cancer) which have been identi-
fied, still only explain a minority of the familial risk.
Moreover, the utility for clinical testing in cancer
remains to be resolved, as the reported associations
do not generally help in predicting the aggressive-
ness of the disease process which may be of greatest
benefit. Analysis of somatic mutations may be more
informative for this purpose notably gene fusion
events such as between TMPRSS2 (transmembrane
protease serine 2) and EGR (ETS related gene) which
commonly occurs in prostate cancer and results in
overexpression of oncogenic transcription fac-
tors.
86,87 The main benefit of the new genetic
knowledge gained through association studies, as
seen with other multifactorial diseases such as
Crohn’s disease, is likely to be in providing novel
insights into disease pathogenesis and potential new
targets for intervention.
Prostate cancer has seen the largest number of
new susceptibility loci identified of any cancer to
date from genome-wide association scans.
85,86
Perhaps most striking among these are the associa-
tions with chromosome 8q24, a genomic region ini-
tially identified from linkage and association
88
together with admixture mapping
89 and subse-
quently genome-wide association studies.
90–93
Figure 4. Genetic association with disease and gene expression. A genome-wide association study of asthma revealed a
strong association with disease at chromosome 17q21. The same SNPs also showed evidence of association with levels of
expression of the nearby gene ORMDL3. Adapted and reprinted by permission from Macmillan Publishers Ltd: Nature,
84
copyright (2007).
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three independent susceptibility loci for prostate
cancer are present containing multiple risk alleles.
For one of these loci, the most significantly asso-
ciated SNP is also associated with colorectal
cancer
94; the region also contains a distinct breast
cancer susceptibility locus.
95 The basis for these
associations remains unresolved although the
proto-oncogene MYC is one of the genes flanking
the region. Indeed, recent evidence shows that the
variant associated with colorectal and prostate
cancer is located in a conserved enhancer element
which interacts with MYC and shows allele-specific
binding of a transcription factor activated in color-
ectal cancer.
96,97
Other disease-associated loci include chromo-
some 10q11.2 in the region of a postulated tumour
suppressor gene MSMB encoding b microsemino-
protein;
90,91 and chromosome 17q12, where intri-
guing evidence of association was found with
increased risk of prostate cancer and protection
from type 2 diabetes for a variant in HNF1B
(TCF2) encoding the transcription factor HNF1
homeobox B.
98 This gene had been previously
implicated in maturity onset diabetes of the young
(MODY)
99 and the association is consistent with epi-
demiological evidence of an inverse risk between
prostate cancer and type 2 diabetes.
100,101
Different variants involving the transcriptional repres-
sor JAZF1 (JAZF zinc finger 1) at chromosome 7p15
have also been found to show contrasting associa-
tions with these two conditions, of protection from
prostate cancer
91 and susceptibility to type 2 diabe-
tes
102 suggesting possible commonality in disease
pathogenesis and new avenues for investigation.
103
Venous thrombosis and
warfarin dose
Venous thromboembolism is a commonly encoun-
tered clinical problem, in which genetic testing for
inherited causes of thrombophilia when clinically
indicated is an important component of patient
care. The genetic basis for venous thrombosis
includes multiple rare variants affecting inhibitors
of the pro-coagulant system such as deficiency of
antithrombin, protein C and protein S, but together
these account for only a small minority of cases of
familial thrombophilia. Other variants common in
the general population and accounting for a signif-
icant genetic risk have been defined including factor
V Leiden which confers activated protein C resis-
tance.
104 Here, a specific SNP in exon 10 of coag-
ulation factor V (F5), the gene encoding coagulation
factor V, results in an amino acid substitution from
arginine to glutamine which makes the protein less
susceptible to degradation. The effect in terms of
disease is large with a 5- or 50-fold increased risk
of venous thrombosis associated with having a
single or two copies of the variant, respectively.
105
Other common variants have also been identified,
notably in the coagulation factor II (F2) gene encod-
ing prothrombin.
106 The indications for thrombophi-
lia screening remain controversial, but evidence
relating to clinical outcomes, absolute and relative
risks is being established to aid clinical decision
making.
107–110
Pharmacogenomics of warfarin therapy
Venous thromboembolism is an important indica-
tion for warfarin therapy, but as a treatment, warfarin
is associated with a high risk of adverse events. This
is related to the narrow therapeutic range of warfarin
and the marked inter-individual variation in
response. This variability is modulated by many fac-
tors including patient age and size, together with
concomitant drug use, diet and the underlying dis-
ease process. Genetic factors also play an important
role and illustrate the developing field of pharmaco-
genomics. Cytochrome P450, family 2, subfamily C,
polypeptide 9 (CYP2C9) encodes a cytochrome
P450 family enzyme involved in elimination of the
more active form of warfarin, and varies in activity
more than 20-fold between individuals. Reduced
enzyme activity and warfarin dosage was associated
with two common alleles of CYP2C9.
111A recent
prospective randomized study of warfarin dosing
incorporating knowledge of CYP2C9 genotype
showed a significant reduction in time to stable
anticoagulation, a reduction of minor bleeding epi-
sodes and the number of monitoring blood tests
required.
112 Genetic variation in vitamin K epoxide
reductase complex, subunit 1 (VKORC1), which
encodes vitamin K epoxide reductase complex 1,
has also been associated with levels of gene expres-
sion and warfarin dosage.
113
This genetic evidence led the US Food and Drug
Administration in August 2007 to approve a label-
ling change for warfarin on package insert such that
‘lower initiation doses should be considered for
patients with certain genetic variations in CYP2C9
and VKORC1 enzymes’.
114 Combining genetic data
for these two genes with information on age, sex and
drug interactions explains 59% of the variance in
warfarin dose.
115 Dosage algorithms incorporating
genetic data are available (http://www.warfarindo
sing.org), and while initial work suggests use of
pharmacogenomic information may be cost-
effective only in patients at high risk of haemor-
rhage
116 the falling costs of genetic testing and
766 J.C. Knightgrowing feasibility of rapid ‘inhouse’ tests mean that
further studies to assess this and clinical utility
across different patient groups will be important,
together with a clearer understanding of molecular
mechanisms and interactions.
117 Consideration of
clinical outcomes, whether in terms of warfarin
use or specific disease traits, is an essential part of
evaluation of the clinical utility of genetic testing for
evidence-based practice but substantial challenges
remain in how to acquire such data.
Conclusions
There has been massive research investment in the
field of human genetics over the last 20 years and
remarkable advances achieved (Table 1). There
remains a gap, however, in terms of this growing
genetic knowledge and translation into clinical
practice, and more broadly with how as a society
we choose to use and manage such information.
As knowledge of the basic science and associated
technologies has advanced, so has our awareness of
the daunting task ahead; the scale and complexity of
genetic variation in human populations is vast and
still incompletely understood, and is manifested in
terms of common disease risk through multiple
genetic, epigenetic and environmental interactions.
It remains a major hurdle to resolve current genetic
associations to specific functionally important
genetic variants and understand their mechanism
of action. We are only now beginning to address
the role of rare and structural variants and much of
the genetic risk in common disease remains to be
explained. We need to more robustly understand the
clinical utility of genetic testing, to appreciate how
this will impact on screening, diagnosis and man-
agement, and to more clearly establish the cost-
effectiveness of these approaches. As genetic testing
for the individual becomes increasingly available
through the private sector, understanding of risk
and the caveats that need to be placed on its inter-
pretation in the context of common disease are crit-
ically important if we are to use and manage such
information. ‘Personalised medicine’ may not yet be
a reality, but the potential of recent genetic
advances are clear. How we use and regulate this
new information for the benefit of patients
requires a more active debate in which clinicians
and other health care professionals should play
a greater role.
Acknowledgements
The author is grateful to friends and colleagues at
the Wellcome Trust Centre for Human Genetics and
John Radcliffe Hospital in Oxford for their helpful
discussions relating to aspects of this review.
Funding
Wellcome Trust (grant 074318 to J.C.K.).
Conflict of interest: None declared.
Table 1 Summary points
There have been radical advances over the last 20 years in our understanding of the nature of the human genome, its
remarkably complex regulation and the extent of genetic diversity between individuals
Genome-wide association studies using hundreds of thousands of polymorphic common genetic markers (single nucleo-
tide polymorphisms or SNPs) across the genome are now allowing many novel disease susceptibility loci to be resolved
in common multifactorial diseases
The proportion of the genetic risk currently explained by such studies remains disappointingly low however future studies
of rarer variants enabled by recent advances in high throughput DNA sequencing, and of structural genomic variants
such as copy number variation, are likely to be highly informative
Genetic variation may modulate the structure or function of the protein encoded by a gene or how gene expression is
regulated at a transcriptional or post transcriptional level, including effects on epigenetic control mechanisms and
alternative splicing
Defining functionally important variants remains challenging and requires analysis in the relevant cell or tissue type in the
specific disease context
Important lessons are being learned from diseases such as Crohn’s disease and HIV/AIDS where many different genetic
variants have been implicated, and new insights into disease pathogenesis and potential drug targets gained, with direct
implications for patient care
Much work remains to be done to establish the clinical utility of genetic testing in common diseases and there is a need
for a broader debate on the ethical implications of current advances in genetics
Pharmacogenomics is likely to have the most immediate impact on the clinical practice of the general physician
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Appendix 1: Glossary
Allele: two alternative forms of a gene, found at a
given chromosomal locus.
Alternative splicing: process controlling how introns
are removed and exons joined together to generate
diversity in protein products encoded by a given
gene.
Chromatin: dynamic protein packaging of DNA
notably involving histone proteins which is impor-
tant to control of gene expression.
Copy number variant: a structural variant involving
gain (for example by insertion or duplication) or loss
(for example by deletion) of regions of DNA more
than 1000 bases in size relative to a reference
sequence; when present at a frequency of greater
than 1% in a population, described as a copy
number polymorphism.
Epigenetic: heritable change not involving a differ-
ence in DNA sequence, for example DNA
methylation.
Genome-wide association study: a study utilizing
several hundred thousand SNP markers across the
genome to look for evidence of statistical associa-
tion, for example between disease cases and con-
trols, with particular SNPs.
Genotyping: a generic term for techniques to
determine genotype, for example which
nucleotide is present in a biallelic SNP, based on
DNA sequencing, array hybridization or a PCR
based method.
Haplotype: the combination of genetic markers or
alleles found along a region of a chromosome.
Heterozygote: individual possessing one of each of
two possible alleles for a given locus (for example
with a G>A SNP, having genotype GA).
Homozygous: individual having identical alleles for
a given locus (for example with a G>A SNP, having
genotype GG or AA).
Linkage: tendency of characters or marker alleles to
be coinherited as responsible loci lie close together
on a chromosome.
Linkage disequilibrium: a measure of statistical asso-
ciation or correlation between alleles at different
loci such that the presence of one allele can be
predicted by another.
Microsatellite: polymorphic DNA sequence invol-
ving repeated DNA sequences (of up to six base
pairs) that are up to 100 base pairs in overall
length; also known as short tandem repeats.
Penetrance: proportion of people with a genetic
variant who manifest the associated phenotype.
Phenotype: observed characteristic.
Positional cloning: identification of a gene based on
chromosomal location rather than function.
Genetics and the general physician 771Promoter: region of noncoding DNA found typically
upstream of a gene that facilitates and regulates
transcription.
Recombination: also known as crossing over, the
process involves breakage of a DNA strand and join-
ing to a new strand, for example, homologous
recombination during meiosis leading to genetic
diversity.
Single nucleotide polymorphisms (SNPs): single-
nucleotide substitutions present at a frequency of
>1% in a population.
Structural genomic variation: describes variation
involving DNA segments more than 1000 bases in
size which may vary in number, position or orien-
tation; for example copy number variants, transloca-
tions and inversions.
Transcription: the process of recruiting RNA poly-
merase and generating RNA from DNA.
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